Cognition Therapeutics (CGTX) Cash & Equivalents (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Cash & Equivalents data on file, last reported at $31.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 89.49% year-over-year to $31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.1 million (up 89.49% YoY) and the FY2025 annual result came in at $36.8 million, up 47.19% from the prior year.
• Cash & Equivalents fell to $31.1 million in Q1 2026 per CGTX's latest filing, from $36.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $51.5 million in Q1 2022 and bottomed at $10.7 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $34.7 million (2024), against an average of $33.5 million.
• The widest annual swing landed in 2022, when Cash & Equivalents soared 461.57%; it then plunged 62.35% in 2025.
• Tracing CGTX's Cash & Equivalents over 5 years: stood at $41.6 million in 2022, then retreated by 28.01% to $29.9 million in 2023, then slipped by 16.42% to $25.0 million in 2024, then soared by 47.19% to $36.8 million in 2025, then declined by 15.43% to $31.1 million in 2026.
• Per Business Quant, the three latest CGTX Cash & Equivalents figures stand at $31.1 million (Q1 2026), $36.8 million (Q4 2025), and $39.3 million (Q3 2025).

Peer Comparison